ASCO Launches New COVID-19-Driven Cancer Registry Leveraging CancerLinQ® and mCODE™

ASCO Launches New COVID-19-Driven Cancer Registry Leveraging CancerLinQ® and mCODE™

The American Society of Clinical Oncology (ASCO) launched a patient registry to help the cancer community better understand 1) how cancer patients are impacted by COVID-19, and 2) what are the disruptions to cancer care due to the global pandemic. Called the ASCO Survey on COVID-19 in Oncology Registry (ASCO), the registry be used for collection of baseline and follow-up data during the COVID-19 pandemic and ongoing at least through 2021.

The Problem

TrialSite News has been monitoring the COVID-19-caused disruption to cancer care around the world. As many cancer patients face dire situations, the strains on healthcare systems can have material and even deadly consequences for those in this community with critical cases. Moreover, little is known about how COVID-19 impacts those with cancer—e.g. what are the pattern of symptoms and severity of COVID-19 among patients with cancer. Regardless, ASCO believes cancer patients and their loved ones, as well as care givers will benefit from a credible data trove that supports and contributes to evolving care models and advocacy to ensure the highest standards of care.

The registry is part of ASCO’s dedicated efforts to provide the...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee